Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside the checkpoint inhibitor ...

Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

USA: A matched-cohort study found that patients with lung cancer, melanoma, or kidney cancer who received PCSK9 inhibitors ...

Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...

Researchers have discovered that activating the pentose phosphate pathway makes antitumor CD8+ T cells more likely to stay in an immature, stem-like, “precursor” state. Combining this metabolic ...

Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad range ...

The trial is active in Europe and Asia across 44 sites in six countries and now includes two in the US.

Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ...